Close Menu

Sponsors

A consortium convened by Friends of Cancer Research has made progress in quantifying sources of TMB assay discordance and created a new test-alignment software tool.

BostonGene will analyze the tumors of patients enrolled in NEC or NEC-affiliated clinical trials and NEC will use the data to help improve treatment responses.  

The initiative will offer a liquid biopsy tool that only requires a blood draw for cancer treatment selection instead of a tissue biopsy. 

Analyzing both circulating tumor DNA and circulating tumor cells, investigators could classify patients into groups with significantly higher and lower recurrence risk.

A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.